Clonal Mesenchymal Stem Cell Exosome Production

The patent segments the heterogeneous stem cell population into individual clonal lines by isolating and cultivating single cells or small cell groups. Each clonal line is then characterized and selected based on specific criteria (e.g., HLA type, functional properties), creating homogeneous subpopulations that can be standardized for therapeutic use. This segmentation approach eliminates donor heterogeneity while maintaining therapeutic efficacy.

The patent changes key parameters of stem cell characterization including HLA typing, age, and molecular profile to establish standardized selection criteria. By controlling and documenting these parameters, the patent creates reproducible conditions for generating exosomes with consistent therapeutic properties, transforming variable donor characteristics into controlled process parameters.

The patent segments the stem cell population into HLA-matched clonal lines, allowing selection of donor-specific or universal HLA types that minimize immune recognition. By isolating and characterizing individual clones with specific HLA profiles, the patent can match donors to recipients or select HLA-matched lines, reducing immune reactions while maintaining therapeutic efficacy.

The patent creates immortalized clonal lines that can be reproduced indefinitely through cell division. These clonal lines serve as standardized copies that can be manufactured consistently without relying on variable donor sources. The clonal exosome production system provides reproducible therapeutic products with reduced immunogenicity compared to primary donor cells.

The patent segments the exosome production system into defined clonal cell lines with characterized properties. Each clonal line produces exosomes with consistent composition and activity because they are derived from identical genetic material. This segmentation enables standardized manufacturing protocols and reliable quality control, transforming the variability of primary cell exosome production into consistent cloned line production.

The patent performs preliminary characterization and selection of clonal lines before exosome production. By pre-characterizing HLA types, functional properties, and molecular profiles of candidate clones, the patent ensures that only suitable lines are used for exosome production. This preliminary action guarantees consistent quality and therapeutic activity in the final exosome products.